



## Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference

May 18, 2026

BURLINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY.

### 2026 Jefferies Global Healthcare Conference

Format: Fireside chat  
Day/Time: Thursday, June 4 at 4:20 PM ET  
Webcast: Link [here](#)

If you are interested in meeting with the Minerva team during the conference, please reach out to your Jefferies representative.

A replay of the presentation will be available on the Company's Investors & Media [Events and Presentations](#) webpage for ninety days following the event.

### About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva's goal is to transform the lives of patients with improved therapeutic options, including roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company's [website](#).

### Contacts:

#### Frederick Ahlholm

Chief Financial Officer  
Minerva Neurosciences, Inc.  
[FAhlholm@minervaneurosciences.com](mailto:FAhlholm@minervaneurosciences.com)

#### Corey Davis, Ph.D.

LifeSci Advisors, LLC  
212-915-2577  
[cdavis@lifesciadvors.com](mailto:cdavis@lifesciadvors.com)